Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy By Ogkologos - August 25, 2025 476 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a meta-analysis performed by the Early Breast Cancer Trialists’ Collaborative Group Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Hormone Replacement Therapy Not Linked with Increased Dementia Risk, Study Finds October 2, 2021 Addressing the Challenges of Cancer Misinformation on Social Media September 9, 2021 ¿Las gammagrafías óseas muestran el cáncer? April 28, 2021 FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial... July 24, 2024 Load more HOT NEWS Pazopanib Shows Promise for Children, Adults with Soft Tissue Sarcomas Young Adult Cancer Awareness Week: Recognizing Adolescent and Young Adults Cancer... A Combination of Oral Mezigdomide Plus Dexamethasone Shows Promising Efficacy in... FDA Grants Accelerated Approval to Adagrasib for KRAS G12C-Mutated NSCLC
